DDInter740 DDInter837
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Flecainide {u} (Compound) binds {v} (Gene) SCN4A
SCN4A {u} (Gene) is bound by {v} (Compound) Phenytoin
Phenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is downregulated by {v} (Compound) Colchicine
Colchicine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levamlodipine
Levamlodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Flecainide {u} (Compound) upregulates {v} (Gene) GARS
GARS {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Flecainide {u} (Compound) upregulates {v} (Gene) AARS
AARS {u} (Gene) is downregulated by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Hydroxychloroquine
Hydroxychloroquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Golimumab
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Flecainide (Compound) binds SCN4A (Gene) and SCN4A (Gene) is bound by Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Colchicine (Compound) and Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine and Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Flecainide (Compound) upregulates GARS (Gene) and GARS (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may lead to a major life threatening interaction when taken with Golimumab
Flecainide (Compound) upregulates AARS (Gene) and AARS (Gene) is downregulated by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab